The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Sep. 08, 2015

Filed:

Dec. 22, 2006
Applicants:

Henry H. Flanner, Montgomery Village, MD (US);

Donald Treacy, Woodbine, MD (US);

Sanna Tolle-sander, North Potomac, MD (US);

Scott Ibrahim, Owings Mills, MD (US);

Marcus Schestopol, Washington, DC (US);

Beth A. Burnside, Bethesda, MD (US);

Inventors:

Henry H. Flanner, Montgomery Village, MD (US);

Donald Treacy, Woodbine, MD (US);

Sanna Tolle-Sander, North Potomac, MD (US);

Scott Ibrahim, Owings Mills, MD (US);

Marcus Schestopol, Washington, DC (US);

Beth A. Burnside, Bethesda, MD (US);

Assignee:

Shionogi Inc., Florham Park, NJ (US);

Attorney:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
A61K 9/22 (2006.01); A61K 9/00 (2006.01); A61K 9/16 (2006.01); A61K 9/20 (2006.01); A61K 9/24 (2006.01); A61K 9/50 (2006.01);
U.S. Cl.
CPC ...
A61K 9/0004 (2013.01); A61K 9/0065 (2013.01); A61K 9/1623 (2013.01); A61K 9/1635 (2013.01); A61K 9/1652 (2013.01); A61K 9/209 (2013.01); A61K 9/2027 (2013.01); A61K 9/2054 (2013.01); A61K 9/2077 (2013.01); A61K 9/2081 (2013.01); A61K 9/2086 (2013.01); A61K 9/501 (2013.01); A61K 9/5015 (2013.01); A61K 9/5026 (2013.01); A61K 9/5042 (2013.01); A61K 9/5073 (2013.01); A61K 9/5084 (2013.01);
Abstract

Disclosed are pharmaceutical products for providing pulses of at least one pharmaceutically active ingredient from a patient's stomach, or from a subsequent gastrointestinal site proximal thereto, for absorption thereof at a site(s) more distal in the gastrointestinal tract than the patient's stomach, or than the subsequent gastrointestinal site proximal thereto. The product comprises first, second, and third pharmaceutical dosage forms, each of which comprises at least one pharmaceutically active agent and a pharmaceutically acceptable carrier. The product is formulated such that at least two of the first, second, and third pharmaceutical dosage forms further comprise means for providing temporary gastric-retention of the at least two of the first, second, and third pharmaceutical dosage forms within the patient's stomach, or at the subsequent gastrointestinal site proximal thereto.


Find Patent Forward Citations

Loading…